<SEC-DOCUMENT>0000200406-19-000002.txt : 20190117
<SEC-HEADER>0000200406-19-000002.hdr.sgml : 20190117
<ACCEPTANCE-DATETIME>20190117084011
ACCESSION NUMBER:		0000200406-19-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190117
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190117
DATE AS OF CHANGE:		20190117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		19530101

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20190117ciz.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3C3B28CBE903DF775F5F386F0E08D69E"></a></div><div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160;&#160;January 17, 2019</font></div><div style="line-height:144%;text-align:center;-sec-extract:summary;"><img src="jnjlogoa06.jpg" alt="jnjlogoa06.jpg" style="height:62px;width:241px;"></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:35%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;08933</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company    </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:right;-sec-extract:summary;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Events.</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As previously disclosed, on October 23, 2018, Johnson &amp; Johnson entered into an agreement to acquire Ci:z Holdings Co., Ltd. (TYO: 4924) (the &#8220;Company&#8221;) for a total purchase price of approximately &#165;230 billion, which equates to approximately $</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#32;billion, using the exchange rate of </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">109.06</font><font style="font-family:inherit;font-size:10pt;">&#32;Japanese Yen to each U.S. Dollar as of 5p.m., New York City time, on January 16, 2019. </font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was completed through a series of transactions that included an all-cash tender offer (the "tender offer") to acquire publicly held shares of the Company, not already held by Johnson &amp; Johnson and its affiliates, for &#165;5,900 per share.&#160;Upon completion of the tender offer and the related transactions, Johnson &amp; Johnson acquired 89% of the outstanding shares of the Company. Johnson &amp; Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company, which markets the Dr Ci:Labo, Labo Labo and Genomer line of skincare products, will now become part of the Johnson &amp; Johnson Family of Consumer Companies.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any EPS impact of the transaction will be included in the 2019 guidance provided on Johnson &amp; Johnson&#8217;s Q4 2018 earnings call.</font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated January 17, 2019 is attached as Exhibit 99.1 to this report. </font></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:144%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:144%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:96px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;font-weight:bold;-sec-extract:exhibit;" href="a20190117ex991ciz.htm"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99.1</font></a><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson Press Release dated January 17, 2019.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:7%;"></td><td style="width:33%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="padding-left:4px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:4px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-left:4px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;January 17, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Renee A. Brutus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renee A. Brutus</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assistant Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20190117ex991ciz.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s554944777af24db984e202b86e71def5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:144%;padding-bottom:12px;text-align:center;"><img src="jnjlogoa06.jpg" alt="jnjlogoa06.jpg" style="height:49px;width:192px;"></div><div style="line-height:209%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contacts:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ernie Knewitz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Donna Lorenson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-6623</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(410) 258-8571</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(917) 697-2318 (M)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">dlorens@its.jnj.com  </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">eknewitz@its.jnj.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mel Tyndale-Biscoe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+65 8798 2475 (Singapore)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Lisa Romanko</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-2034</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Johnson &amp; Johnson Completes Acquisition of Ci:z Holdings Co., Ltd. </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Acquisition Expands J&amp;J&#8217;s Portfolio of Science-based Dermocosmetic Beauty Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NEW BRUNSWICK, NJ, January 17, 2019</font><font style="font-family:inherit;font-size:11pt;">&#32;- Johnson &amp; Johnson (NYSE:JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the &#8220;Company&#8221;) for a total purchase price of approximately &#165;230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for &#165;5,900 per share.  Johnson &amp; Johnson plans to acquire the remaining shares of the Company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the Company from the Tokyo Stock Exchange. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company, which markets the Dr Ci:Labo, Labo Labo and Genomer line of skincare products, will now become part of the Johnson &amp; Johnson Family of Consumer Companies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;The addition of Dr Ci:Labo, Labo Labo and Genomer to our franchise strengthens our growing beauty portfolio with unique dermocosmetic innovation,&#8221; said Jorge Mesquita, Worldwide Chairman, Johnson &amp; Johnson Consumer. &#8220;We are very pleased to complete this important transaction and look forward to bringing efficacious, science-backed skincare products to our health and beauty consumers around the world.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any EPS impact of the transaction will be included in the 2019 guidance provided on Johnson &amp; Johnson&#8217;s Q4 2018 earnings call. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Johnson &amp; Johnson </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">At Johnson &amp; Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOTE CONCERNING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential transaction between&#160;Johnson &amp; Johnson&#160;and&#160;the Company. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of&#160;Johnson &amp; Johnson&#160;and&#160;the Company. Risks and uncertainties include, but are not limited to: the satisfaction of closing conditions for the transaction, including the receipt of regulatory approvals for the transaction; the tender of the requisite amount of the outstanding shares of the Company; the possibility that the transaction will not be completed in the expected timeframe or at all; the potential that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; uncertainty of commercial success for new and existing products; manufacturing difficulties and delays; economic conditions, including currency exchange and interest rate fluctuations; competition, including technological advances, new products and patents attained by competitors; changes to applicable laws and regulations, including tax laws and domestic and foreign health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to the ability of the&#160;Johnson &amp; Johnson&#160;Family of Companies to successfully integrate the products, employees and operations of&#160;the Company, as well as the ability to ensure continued performance or market growth of&#160;the Company&#8217;s products. A further list and description of these risks, uncertainties and other factors can be found in&#160;Johnson &amp; Johnson's&#160;publicly available filings with the&#160;U.S. Securities and Exchange Commission. Copies of these filings, as well as subsequent filings, are available online at&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:11pt;">,&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.jnj.com</font><font style="font-family:inherit;font-size:11pt;">&#32;or on request from&#160;Johnson &amp; Johnson. Johnson &amp; Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>jnjlogoa06.jpg
<TEXT>
begin 644 jnjlogoa06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @!$<C$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8T+C P /_; $,  @$! 0$!
M @$! 0(" @("! ," @("!00$ P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&" L,"PH,"0H*"O_; $,! @(" @("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_  !$( "\
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MM-M(Y-R->3[<[Y4>*),95V<*GO\ \ +OQGJ/P3\(ZA\1]7_M'Q%/X:L)=8U
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M;)'ZU^9?_!6#]GV[MI/BU9? 37HK/3?$7@6/Q7\8M&DM/,BCGL)U?3[F!O\
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M>]S<THTXT^;X5RIJ-^7WO>E+WM;*; ]*,#TH'2BNK0^?"C ]*** "C ]***
.."C SG%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
